Interesting to see how the ptx200’s progression-free survival data is holding up on the phase 1b Ovarian readout;
AstraZeneca and Merck & Co. have just had a set back:
https://www.biopharmadive.com/news/astrazeneca-merck-lynparza-cediranib-ovarian-cancer/574019/
"Measured by progression-free survival, or the length of time patients live without their tumors getting larger or spreading, the Lynparza-cediranib combination did no better than platinum-based chemotherapy."
- Forums
- ASX - By Stock
- Ann: Encouraging data from PTX-200 ovarian cancer trial
Interesting to see how the ptx200’s progression-free survival...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.6¢ |
Change
0.003(6.98%) |
Mkt cap ! $34.62M |
Open | High | Low | Value | Volume |
4.3¢ | 4.6¢ | 4.3¢ | $58.67K | 1.309M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 150000 | 4.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.7¢ | 525019 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 150000 | 0.045 |
1 | 100000 | 0.044 |
5 | 440115 | 0.043 |
5 | 492851 | 0.042 |
4 | 978661 | 0.041 |
Price($) | Vol. | No. |
---|---|---|
0.047 | 525019 | 3 |
0.048 | 308027 | 2 |
0.050 | 60539 | 2 |
0.052 | 204000 | 2 |
0.054 | 131000 | 3 |
Last trade - 11.21am 22/08/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |